Konakion

Konakion

Injection

🧬 Phytomenadione 🏢 Radiant Pharmaceuticals Ltd.
Generic Name Phytomenadione
Manufacturer Radiant Pharmaceuticals Ltd.
Unit Price 2 mg ampoule: ৳ 98.00 (1 x 5: ৳ 490.00)

🔹 Indications

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Pharmacology

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Dosage & Administration

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Interaction

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Contraindications

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Side Effects

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Precautions & Warnings

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

🔹 Storage Conditions

Konakion (Vitamin K-1) is indicated in following indications-
  • Prophylaxis and treatment of haemorrhagic disease in the newborn.
  • Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII, IX and X) of various etiologies, including overdosage of courmarin-type anticoagulants, their combination with phenylbutazone, and other forms of hypovitaminosis K (e.g. in obstructive jaundice as well as liver and intestinal disorders, and after prolonged treatment with antibiotics, sulphonamides or salicylates).
  • Prevention and treatment of bleeding due to vitamin K deficiency.

💡 Frequently Asked Questions

Konakion (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...
Konakion (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...
Konakion (Vitamin K-1) is indicated in following indications- Prophylaxis and treatment of haemorrhagic disease in the newborn. Haemorrhage or risk of haemorrhage as a result of severe hypoprothrombinemia (i.e. deficiency of clotting factors II, VII...

User Reviews

No reviews yet!
Be the first to share your experience.

Write a Review